In this video, I will cover the recent updates regarding Novo Nordisk (NYSE: NVO) and whether or not the dip is worth buying over Eli Lilly (NYSE: LLY). Watch the short video to learn more, consider subscribing, and click the special offer link below.
*Stock prices used were from the trading day of Dec. 20, 2024. The video was published on Dec. 22, 2024.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $349,279!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $48,196!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $490,243!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
See 3 “Double Down” stocks »
*Stock Advisor returns as of December 16, 2024
Neil Rozenbaum has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
